B细胞急性淋巴细胞白血病中更快的临床决策:单管12色流式细胞术改善诊断与微小残留病随访
本研究描述了一种优化的单管12色流式细胞术抗体组合,用于B细胞前体急性淋巴细胞白血病(BCP-ALL)的诊断和微小残留病(MRD)监测。该方法利用CD43和CD81等标志物区分正常造血前体细胞与白血病细胞,采用双DFN/LAIP策略结合主成分分析,与qPCR结果强相关(r=0.87),可在无诊断样本时进行MRD分析,并在单管内2小时内完成染色/裂解/洗涤。
要点
- 单管12色流式 panel 可同时用于 BCP-ALL 诊断和 MRD 监测。
- CD43 和 CD81 等标志物增强 BCP-ALL 细胞检测特异性。
- 与 qPCR 结果强相关(r=0.87),支持 MRD 监测的稳健性。
核心结论
- 基于流式细胞术的方法提高了 BCP-ALL 诊断效率和 MRD 管理,为临床实验室提供了补充方法。
研究设计与样本
- 本研究描述了一种优化的单管12色流式细胞术抗体组合,用于 BCP-ALL 诊断和 MRD 监测。
主要发现
- 该方法使用 CD43 和 CD81 两个特定标志物稳健区分造血前体细胞和 BCP-ALL 细胞。
- CD73、CD66c 和 CD49f 等其他标志物增强了 BCP-ALL 细胞检测的特异性。
- 基于双 DFN/LAIP 策略结合主成分分析的方法可用于所有患者,即使无诊断样本也可进行 MRD 分析。
- 该方法与 qPCR 结果强相关(r = 0.87),证实了 MRD 监测的稳健性。
- 通过单管内染色/裂解/洗涤方法(<2 h)简化和加速了分析前过程。
关键数值与推荐
- 与 qPCR 结果的相关系数 r = 0.87。
- 单管内染色/裂解/洗涤方法耗时 <2 h。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Assessing minimal residual disease (MRD) in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost-effective method that typically uses leukaemia-associated immunophenotype (LAIP) or different-from-normal (DFN) approaches for MRD assessment. This study describes an optimized 12-colour flow cytometry antibody panel designed for BCP-ALL diagnosis and MRD monitoring in a single tube. This method robustly differentiated hematogones and BCP-ALL cells using two specific markers: CD43 and CD81. These and other markers (e.g. CD73, CD66c and CD49f) enhanced the specificity of BCP-ALL cell detection. This innovative approach, based on a dual DFN/LAIP strategy with a principal component analysis method, can be used for all patients and enables MRD analysis even in the absence of a diagnostic sample. The robustness of our method for MRD monitoring was confirmed by the strong correlation (r = 0.87) with the qPCR results. Moreover, it simplifies and accelerates the preanalytical process through the use of a stain/lysis/wash method within a single tube (<2 h). Our flow cytometry-based methodology improves the BCP-ALL diagnosis efficiency and MRD management, offering a complementary method with considerable benefits for clinical laboratories.
引用
- Lebecque B, Besombes J, Dannus LT, et al. Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up. Br J Haematol. 2024. PMID: 38432068. doi:10.1111/bjh.19390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。